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Abstract: In parallel to our better understanding of the role of the immune system in neurologic diseases, there has  
been an increased availability in therapeutic options for autoimmune neurologic diseases such as multiple sclerosis,   
myasthenia gravis, polyneuropathies, central nervous system vasculitides and neurosarcoidosis. In many cases, the   
purported benefits of this class of therapy are anecdotal and not the result of good controlled clinical trials. Nonetheless, 
their potential efficacy is better known than their adverse event profile. A rationale therapeutic decision by the clinician 
will depend on a comprehensive understanding of the ratio between efficacy and toxicity. In this review, we outline  
the most commonly used immune suppressive medications in neurologic disease: cytotoxic chemotherapy, nucleoside 
analogues, calcineurin inhibitors, monoclonal antibodies and miscellaneous immune suppressants. A discussion of their 
mechanisms of action and related toxicity is highlighted, with the goal that the reader will be able to recognize the most 
commonly associated toxicities and identify strategies to prevent and manage problems that are expected to arise with 
their use. 
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INTRODUCTION 
  Advances in our understanding of the intricate interaction 
between the immune system and the nervous system have 
translated into the routine use in clinical practice of immune 
suppressive therapy for neurologic disease of presumed or 
confirmed autoimmune etiology. Diligent research has led to 
therapies that can alter or modify the course of the disease in 
multiple sclerosis (MS), myasthenia gravis (MG), acute and 
chronic demyelinating polyneuropathies, and other neu-
rologic illnesses (Table 1). The neurologist must be aware 
not only of the potential benefit but also of the side effect 
profile to utilize the appropriate immune suppressive drug 
with the optimal therapeutic ratio for the individual patient. 
  In this review, we will discuss the medication-related 
toxicity of immunosuppressive treatments most widely used 
in neurology, as well as new medications that are advanced 
in the drug development pipeline with potential for Food and 
Drug Administration (FDA) approval. Due to the large num-
ber of therapies and side effects, an exhaustive discussion of 
all medications is beyond the scope of this article. We will 
classify the drugs according to their professed mechanism of 
action, briefly review their indication in neurologic disease, 
and then describe the most frequent adverse effects includ-
ing, when appropriate, recommendations for monitoring and 
management (Table 2). 
CORTICOSTEROIDS 
  Corticosteroids depress the immune system by stabilizing 
lysosomal membranes, decreasing migration of leukocytes,  
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reducing the number of immune cells, and inhibiting the 
production of cytokines and other immune modulators [1]. 
Being the most widely used immunomodulatory medication 
in neurology, they are prescribed for MS, MG, chronic in-
flammatory demyelinating polyradiculoneuropathy (CIDP), 
central nervous system (CNS) vasculitides and neurosarcoi-
dosis to name a few. 
  Corticosteroid side effects depend on daily dose, dosing 
frequency, and duration of treatment. Brief courses of these 
drugs, even at very high doses are typically well tolerated. 
Prolonged use can cause a multitude of symptoms that range 
from skin changes to fatal adrenal suppression. The most 
common side effects of chronic use include: hypertension, 
cushingoid habitus; skin changes;  proximal myopathy;   
psychological disturbances;  hyperglycemia and diabetes; 
peripheral edema; acid peptic disease; infections; osteoporo-
sis and aseptic necrosis of bone. Patients on chronic treat-
ment should be monitored for osteoporosis and will fre-
quently require of the use of bisphosphonates. Dosing corti-
costeroids treatment on alternate days is thought by many to 
be associated with fewer side effects but there have been no 
good comparative trials to prove this claim. 
CYCLOPHOSPHAMIDE 
  As an alkylating agent, cyclophosphamide interferes   
with the growth of rapidly proliferating cells, including   
lymphocytes, by intercalating DNA [2]. It is used off-label  
in refractory MS, neurosarcoidosis and CNS vasculitides. 
  Cyclophosphamide therapy is associated with nausea and 
vomiting, hair loss, skin irritation, liver enzyme abnormali-
ties and marrow depression. Infertility occurs in both men Toxicities of Immunosuppressive Treatment of Autoimmune Neurologic  Current Neuropharmacology, 2011, Vol. 9, No. 3    469 
Table 1.  Immunosuppressive Medications Used for Treatment of Autoimmune Neurologic Diseases 
Immunosuppressive Therapy  FDA Approved Indication  Generally Accepted Indication  Investigational 
Cyclophosphamide  Leukemia, Lymphoma, carcinoma  Neurosarcoidosis, MS, Primary or 
secondary CNS vasculitis 
 
Mitoxantrone MS,  Prostate cancer    
Intravenous immunoglobulin  CIDP  MG, LEMS, GBS, MMN   
Azathioprine  Renal transplantation, Rheumatoid arthritis  MG CIDP,  Neurosarcoidosis 
Mycophenolate  Renal, hepatic and cardiac transplantation  MG CIDP,  Neurosarcoidosis 
Cyclosporine  Renal, hepatic and cardiac transplantation  MG MS 
Tacrolimus  Renal, hepatic and cardiac transplantation  MG  
Cladribine  Hairy cell leukemia   MS,  Neurosarcoidosis 
Natalizumab MS,  Crohn’s disease    
Rituximab  Non-Hodgkin’s lymphoma, Rheumatoid arthritis    MS, CIDP, CNS vasculitis 
Alemtuzumab  B-cell chronic lymphocytic leukemia   MS 
Fingolimod     MS 
MS- Multiple sclerosis, MG – Myasthenia gravis, GBS – Guillain-Barre Syndrome, CIDP - Chronic inflammatory dyemelinating polyradiculoneuropathy, LEMS – Lambert-Eaton 
myasthenic syndrome, MMN – Multifocal motor neuropathy CNS – Central nervous system 
 
Table 2.  Toxicities of Immunosuppressive Medications 
Drug MOA  Major  Toxicity 
Cytotoxic chemotherapy 
Cyclophosphamide Intercalates  DNA  Leucopenia, hemorrhagic cystitis, bladder malignancy, 
myeloproliferative disorders, Infertility 
Mitoxantrone  Intercalates DNA, interferes  
with RNA synthesis 
Cardiomyopathy, leukemia  
(myeloproliferative), Infertility 
Chemotherapy Immunosuppresant 
Azathioprine  Inhibition of purine nucleotide synthesis  Leucopenia, pancreatitis, hepatotoxicity, malignancy 
Mycophenolate Inhibition of guanosine nucleotide synthesis  Gastrointestinal symptoms, lymphopenia, infections 
Cladribine  Inhibition of purine nucleotide synthesis  Lymphopenia 
Monoclonal antibody – transmigration inhibition 
Natalizumab  Prevents trans-migration of lymphocytes 
across the blood-brain barrier 
PML and other opportunistic infections 
Monoclonal antibody – Lymphocyte depletion 
Rituximab  Depletion of B-lymphocytes  PML and other opportunistic infections 
Alemtuzumab  Depletion of lymphocytes  Autoimmune disease (ITP, Grave’s disease),  
leucopenia 
Lymphocytic sequestration 
Fingolimod  Lymphatic sequestration of lymphocytes  Bradycardia, infection 
Non-specific antibody binder 
Intravenous immunoglobulin  Modulation of the expression and  
function of Fc receptors 
Aseptic meningitis, anaphylaxis, renal failure 
MOA - Mechanism of action, PML - Progressive multifocal leukoencephalopathy, ITP - Immune thrombocytopenic purpura. 470    Current Neuropharmacology, 2011, Vol. 9, No. 3  Lallana and Fadul 
 
and women and the reported incidence of amenorrhea is as 
high as 42% with 24% becoming permanent [3]. 
  A potentially life threatening side effect is the develop-
ment of acute hemorrhagic cystitis. Acrolein, a metabolite of 
cyclophosphamide, enters the uroepithelial cells and acti-
vates intracellular pathways which result in peroxynitrite 
production that ultimately leads to necrotic cell death [4, 5]. 
The use of intravenous fluid hydration and prophylactic 
mesna, a chelating agent for acrolein, has significantly low-
ered the incidence of this complication [6, 7]. However, 
since cyclophosphamide doses used in MS are less than 
1g/m
2, there is usually no need for prophylactic mesna in this 
setting. 
  Bladder cancer, also thought to be due to accumulation of 
acrolein, has an estimated incidence of 5% at 10 years and 
16% at 15 years [8]. A twenty year follow-up study showed 
that those who developed cancer in relation to cyclophos-
phamide had received a higher dose of the medication and 
that it can occur many years after its discontinuation [9]. 
Cardiac side effects have been observed after high doses of 
cyclophosphamide (exceeding 200 mg/kg) and the abnor-
malities range from mild electrocardiographic changes to 
fatal cardiomyopathy [10, 11]. Congestive heart failure and 
pericarditis may occur within the first 10 days of treatment. 
The risk factors include prior anthracycline/anthracenedione 
therapy, age >50 years or chest irradiation [10, 12]. While 
these risk factors are not absolute contraindications, caution 
must be used when considering cyclophosphamide therapy in 
these patients. 
MITOXANTRONE 
  Mitoxantrone is an anthracenedione that crosslinks   
DNA, interferes with RNA synthesis and inhibits the   
enzyme topoisomerase II [13]. It is approved by the FDA  
for reducing neurologic disability and/or the frequency   
of clinical relapses in patients with secondary (chronic)   
progressive, progressive relapsing, or worsening relapsing-
remitting MS. 
  The most common serious toxicity is myelosuppression 
that appears about 10 -14 days after treatment. Leucopenia is 
more frequently seen than thrombocytopenia and anemia. 
Transaminase elevation is noted in up to 15% of patients but 
this is typically transient. Secondary amenorrhea occurs in 
up to 25% of MS patients [14]. Mitoxantrone is moderately 
emetogenic, and rarely causes mucositis and hair loss. 
  A serious side effect of mitoxantrone is cardiotoxicity 
that usually appears after large cumulative doses. Drug-
related congestive heart failure occurs in 2.6–6.0% of pa-
tients who received cumulative doses of up to 140 mg/m
2 as 
treatment for leukemia or solid tumours [15]. The incidence 
of asymptomatic left ventricular ejection fraction (LVEF) 
that is <50% is approximately 5% in MS. When treatment is 
limited to a cumulative lifetime dose of 60 mg/m
2, the ob-
served incidence is <0.2% [16]. Due to these complications, 
mitoxantrone must not be given to patients with underlying 
cardiac disease especially cardiomyopathy, with LVEF <50%, 
who previously received treatment with other anthracyclines 
or had mediastinal irradiation. The FDA recommends   
quantitative evaluation of LVEF prior to each treatment and 
yearly after its completion. A recent study suggests that 
measurement of brain natriuretic peptide in blood may be a 
useful marker of sub-clinical cardiac injury [17]. 
  Topoisomerase II inhibitors such as mitoxantrone have 
also been associated with the development of secondary   
leukemia, most frequently acute myeloid leukemia [18]. The 
early experience in MS suggested a low incidence of the 
complication, estimated at 0.21%[19-20] but recent studies 
suggest a higher incidence of up to 3.3% [21]. Most cases 
have occurred in patients receiving >60 mg/m
2 of mitoxan-
trone. There was also an initial assumption that the prognosis 
of treatment-associated leukemia was better [22], but some 
authors report a mortality rate as high as 24% [23]. A post 
marketing report found 39 cases of secondary leukemia in 
the United States from 2003 to 2007. Most of the cases were 
either acute myeloid leukemia (38.5%) or acute promyelo-
cytic leukemia (33.3%). While these reports were of a spon-
taneous nature and the incidence rate cannot be estimated, 
there needs to be an increased vigilance towards the occur-
rence of secondary leukemia. 
INTRAVENOUS IMMUNOGLOBULIN 
  Intravenous immunoglobulin (IVIg) is prepared from 
pooled plasma and has a complex mode of action that is not 
completely defined. It is thought to modulate the expression 
and function of Fc receptors, interfere
 with the activation of 
complement and the cytokine network,
 produce antiidiotypic 
antibodies, and affect the functions of lymphocytes [24]. 
IVIg is indicated in the treatment of CIDP, and is used   
off-label in Guillain-Barre syndrome, MG, multifocal motor 
neuropathy, and dermatomyositis. 
  About 10% of those receiving IVIg experience side ef-
fects that are generally mild [25]. The most common are 
headaches, chills, myalgias, and chest discomfort that occur 
during infusion. Less frequent side effects are dyspnea, back 
pain, nausea, vomiting, diarrhea, blood pressure changes, 
and tachycardia that are usually transient and subside with-
out intervention. After the infusion, patients sometimes re-
port nausea, loss of appetite, fatigue, and fever. Skin reac-
tions of uncertain etiology are also known to occur within 24 
hours after infusion [26]. Pre-treatment with analgesics, non-
steroidal anti-inflammatories, antihistamines, or low-dose 
corticosteroids has been frequently observed to be beneficial 
in preventing these reactions. 
  Aseptic meningitis is an infrequent adverse reaction of 
immunoglobulin therapy and has been reported to have an 
incidence as high as 11% [27] although most reports estimate 
it to be 1% [26]. It occurs within 24 hours of infusion and 
can last 3-5 days before spontaneously resolving. 
  There is a risk for a severe anaphylactic reaction in pa-
tients who have IgA deficiency. The anti-IgA antibodies in 
the serum of patients with this deficiency form an immune 
complex with the traces of IgA in the infused IVIg. Checking 
for IgA levels can screen patients at risk and the use of IgA 
depleted IVIg can prevent this reaction [28]. 
  Elderly patients, poorly hydrated individuals and patients 
with diabetes or impaired kidney
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acute renal failure [26]. Additionally, patients who receive 
high doses or high infusion rates of IVIg or have a history of 
prior thromboembolism are at risk of thromboembolic events 
[29]. 
  The possibility of transmission of infectious agents is 
present whenever IVIg is used although the occurrence is 
rare. The use of IVIg remains
 relatively safe compared with 
other immunosuppressive drugs or interventions. 
AZATHIOPRINE 
  Azathioprine, a prodrug of 6-mercaptopurine (6-MP), 
interferes in purine nucleotide synthesis and metabolism 
which makes it an effective inhibitor of lymphocyte prolif-
eration. It has been used off-label in MS and MG. 
  This medication causes nausea and vomiting in about 
22% of patients with a third having severe enough symptoms 
to cause its discontinuation [30]. These side effects start soon 
after initiation of treatment. Pancreatitis and hepatotoxicity 
have also been reported and these symptoms occur within the 
first 3-6 months [31, 32]. There are frequent liver enzyme 
elevations that resolve spontaneously with dose decreases or 
discontinuation. 
  Monitoring of complete blood counts is recommended 
during azathioprine therapy due to leucopenia and thrombo-
cytopenia. In the rheumatology literature, the incidence of 
leucopenia is about 27% and thrombocytopenia 5% [33, 34]. 
Dosage adjustments are necessary when leucocyte count 
becomes lower than 3000/uL. Macrocytic anemia has been 
reported and is treated with folate supplementation [35]. 
Thiopurine S-methyltransferase (TPMP) catalyzes 6-MP to 
its inactive metabolite methyl-6-mercaptopurine. Patients 
who are deficient of TPMP may be more sensitive to the 
myelosuppressive effects. Additionally, patients on concur-
rent therapy with drugs which may inhibit TPMP (olsa-
lazine) or xanthine oxidase (allopurinol) may be susceptible 
to the same sensitivity. A high incidence of azathioprine in-
tolerance in MS patients has been reported which is purport-
edly secondary to genetic polymorphysism in the enzymes 
metabolizing the drug [36].  
  Malignancies are known to occur in azathioprine treated 
patients but the exact incidence is unknown. Although   
originally thought to be due to the immune suppression caused 
by the drug, several studies have shown that azathioprine has 
a direct mutagenic effect [37-39]. Lymphoma (Fig. 1) is the 
most well known of these rare malignancies and is estimated 
to occur in 0.5% of renal transplant patients [40]. Other   
tumors associated with azathioprine are: squamous cell   
carcinomas of the skin, Kaposi's sarcoma, in situ carcinomas 
of the cervix, carcinomas of the vulva and perineum, hepato-
biliary carcinoma, and mesenchymal tumors [41, 42].  
 Serious  infections are a constant hazard for patients re-
ceiving azathioprine. The overall infection rate is estimated 
to be approximately 9% [34]. Fungal, viral, bacterial, and 
protozoal infections have been observed and must be treated 
with the appropriate antimicrobial therapy. 
MYCOPHENOLATE 
  This drug inhibits purine synthesis and has mostly been 
used off-label in MG [43, 45, 46]. Mycophenolic acid inhibits 
the enzyme inosine monophosphate dehydrogenase, and as  
a consequence, it decreases de novo guanosine nucleotide 
synthesis. Since lymphocytes are dependent on the de novo 
synthesis of purines, this deficiency results in significant 
reduction of lymphocyte proliferation. Mycophenolate has 
also been shown to directly induce programmed cell death of 
activated human T cells and inhibit the antibody production 
of activated B cells [47, 48]. As a result, lymphopenia is the 
most common adverse reaction. At therapeutic doses, lym-
phopenia is noted in about 2% of myasthenics [49]. Anemia, 
neutropenia and thrombocytopenia are also seen [50]. These 
hematologic side effects are easily reversed with lowering 










Fig. (1). A 54 year old woman with auto-immune hepatitis on 
treatment with azathioprine for five years who presented with sub-
acute neurologic symptoms of right facial drooping and loss of 
vision in the right eye. MRI revealed a ring-enhancing pontine le-
sion. Pathological examination proved this to be large B-cell pri-
mary central nervous system lymphoma (PCNSL). The imaging 
characteristics of the tumor were that of a ring-enhancing mass 
typical of PCNSL found in HIV patients. 
  Mycophenolate causes nausea, vomiting, diarrhea and 
cramping but these side effects are self-limited and do   
not usually cause discontinuation of treatment [51]. In a   
prospective study of patients with MG, the incidence of   
mild nausea was 8% and severe gastrointestinal symptoms 
1% [49]. Gastrointestinal bleeding is occasionally seen   
in transplant patients receiving mycophenolate but has   
not been reported in rheumatologic or neurologic literature. 
This medication has been associated with transient elevations 
of liver enzymes but no other significant hepatotoxicity   
[52]. 
  There have been case reports of lymphoma and other 
malignancies associated with mycophenolate treatment. 
However, in a prospective observational study of renal trans-
plant patients treated with mycophenolate, there was no   
evidence of increased risk for malignancy relative to other 
immunosuppressive treatments [53]. This suggests that the 
increased rate of malignancy is associated with the immune 
suppression and not a direct mutagenic effect. 
  Mycophenolate treatment can increase the risk of   
opportunistic infections such as activation of latent viral   
infections. Progressive multifocal leukoencephalopathy 
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apathy, confusion, cognitive deficiencies, visual changes and 
ataxia [54]. 
CLADRIBINE 
  Cladribine is another medication that inhibits purine   
synthesis. It is an adenosine deaminase-resistant
  purine  
nucleoside [55] that causes lymphocyte apoptosis [56]. A 
recent trial of oral therapy
  in patients with relapsing–
remitting MS revealed a significantly lower
 annualized rate 
of relapse,
  higher relapse-free rate, lower risk of 3-month
 
sustained progression of disability and significant reductions 
in the brain lesion
  count on magnetic resonance imaging 
(MRI) [57]. 
  The most common and serious side effect of the oral   
administration is lymphopenia, although moderate to severe 
neutropenia, thrombocytopenia and pancytopenia may also 
occur. 
  Reactivation of herpes zoster, varicella and tuberculosis 
due to the immune suppression have been reported. Mild 
respiratory tract infection, urinary tract infection, and subcu-
taneous abscess have also been observed. Hepatobiliary dis-
orders like cholelithiasis, infectious hepatitis and cholecysti-
tis were also seen. There were three cases of cancer: a mela-
noma and carcinomas of the pancreas and
 ovary. Peripheral 
neuropathy, a known rare side effect of the injectable   
cladribine, has not been reported with the oral preparation. 
CYCLOSPORINE 
  Cyclosporine, a polypeptide immunosuppressant agent 
[58], preferentially inhibits clonal expansion of activated   
T-helper cells while allowing the activation and expression 
of T-suppressor lymphocytes [44]. The drug binds to the 
cytosolic protein cyclophilin to form a complex that inhibits 
calcineurin, an inducer of the production of interleukin-2. It 
is used off-label in the treatment of MG and MS. 
  The most common limiting adverse event of this medica-
tion is nephrotoxicity, both acute and chronic, which was 
first recognized in renal transplant patients. The acute neph-
rotoxicity is usually reversible and believed to be due to a 
vasoconstriction of the afferent arterioles [59]. The irreversi-
ble chronic form is a consequence of interstitial fibrosis that 
develops after 6 to 12 months of treatment [60] and increases 
the risk of end-stage renal disease and need for hemodialysis. 
Since nephrotoxicity is dose dependent and cyclosporine has 
a narrow therapeutic range, blood concentration should be 
regularly monitored. However, drug monitoring does not 
always prevent nephrotoxicity. Renal function monitoring by 
laboratory parameters is required and at the earliest signs of 
nephrotoxicity, the medication should be discontinued. 
  Hypertension is a common side effect that is easily   
managed with medication. Potassium-sparing diuretic agents 
are avoided due to the occasional hyperkalemia associated 
with cyclosporine use. Additionally, calcium channel block-
ers, which may have some beneficial effect on renal afferent 
arteriolar blood flow, can interfere with cyclosporine   
metabolism and its use is not recommended in this group   
of patients. 
  Infrequent mild to moderate adverse events include hirsu-
tism, tremor, gum hyperplasia, diarrhea, cramps, anorexia, 
confusion and paresthesias. Similar to other immunesuppres-
sants, there is a recognized increase in susceptibility to   
infection and possible development of lymphoma and other 
neoplasms [61]. 
TACROLIMUS 
  This is another immune suppressive medication that in-
hibits, by an unknown mechanism, T-lymphocyte activation. 
Like cyclosporine, it has a macrolide molecule and inhibits 
calcineurin. Its main use has been in organ transplantation 
and while its main limiting factor is also nephrotoxicity, it 
has not been a significant issue in the published studies treat-
ing patients with MG [62-67]. In these studies, there were 
only sporadic cases of treatment limiting side effects. There 
was one case of elevated serum creatinine in the setting of 
hypertension [65], one case of severe headache, and one case 
of severe eye pain [63]. However, there were three cases of 
malignancy which may or may not be related to the treat-
ment since these occurred within 4 to 6 months of initiating 
therapy and patients in this study had previously been 
chronically treated with cyclosporine [67]. 
  Other side effects include hypomagnesemia, paresthesias, 
tremor, diarrhea, constipation, hypertension, abdominal pain, 
and hyperkalemia. Severe infections have been reported in 
transplant patients but were not observed to be significant in 
MG studies. 
  Tacrolimus appears to be a well tolerated treatment but 
close observation of patients on this medication is necessary 
because of its potential for serious side effects. 
NATALIZUMAB 
  Natalizumab is a humanized monoclonal antibody that 
targets the alpha-4 subunit of integrins on the surface of 
lymphocytes. This interaction prevents the integrin from 
binding to the endothelial receptor, vascular-cell adhesion 
molecule-1 [68], thereby effectively blocking the transmigra-
tion of lymphocytes across the blood-brain barrier. When 
used in patients with
 relapsing MS, it reduces the risk of the 
sustained progression
  of disability and the rate of clinical 
relapses [69, 70]. 
  The most serious adverse event associated with its use is 
PML. The first 2 reports of PML were seen in patients who 
had received natalizumab in combination with intramuscular 
interferon beta 1a [71, 73]. Following these two events, a 
review of all patients treated revealed that there was a third 
case of PML in a Crohn's disease patient who had been heav-
ily pretreated with immunosuppressants [72]. This prompted 
the manufacturer to voluntarily withdraw the medication 
from the market in February, 2005. After review of safety 
information and no further occurrences of PML, a prescrip-
tion safety risk monitoring system was devised and the 
medication was allowed to return to the market in June, 
2006. At that time, PML was believed to occur only in im-
munosuppressed individuals or if used in combination ther-
apy with an immunomodulator. In June, 2008, one of the 
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monotherapy was found. The FDA reports that as of January 
21, 2010 there have been 31 confirmed cases of PML. De-
spite the number of cases, the FDA believes that its clinical 
benefits continue to outweigh the potential risks. Based on 
their information, there have been no reports of PML in pa-
tients treated for less than 12 months and that the incidence 
of PML in patients with at least 24 months of treatment is 
about 1 per 1000 patients [74]. 
  JC virus infection of oligodendrocytes in an immune 
suppressed state is the cause of PML. The virus is present  
in 58% of the general population, indicating asymptomatic 
current or previous infection [75]. In MS patients, it is   
believed that natalizumab reduces immune surveillance   
in the CNS, thereby causing regional immune compromise. 
The virus is reactivated from the kidney or lymphatic tissue 
which is then disseminated into the CNS. However, other 
authors believe that the JC virus is ubiquitous and is   
also latent in the brain [76]. Prior to natalizumab, PML was 
virtually unseen in the MS population. 
  Clinically, the symptoms are difficult to distinguish from 
a severe MS relapse. Once PML is suspected, natalizumab 
must be discontinued and MRI should be done immediately. 
However, there is not one specific PML MRI appearance. 
Most commonly, PML appears as a large white matter 
T2/FLAIR hyperintensity that can involve the adjacent gray 
matter without producing any significant mass effect.   
Polymerase chain reaction (PCR) analysis of cerebrospinal 
fluid for JC virus DNA is very sensitive and specific for the 
diagnosis [77, 78]. In cases where suspicion remains strong 
despite a negative cerebrospinal fluid PCR, a brain biopsy 
may be indicated. Once the diagnosis is confirmed, immune 
reconstitution must be facilitated. Various antiretroviral 
drugs [79, 80] have been used, as well as other medications 
such as mefloquine and mirtazapine [81] but evidence of 
their efficacy is lacking. Several authors have advocated 
plasma exchange and immunoabsorption to remove any   
remaining natalizumab in the patient's circulation [82]. How-
ever, abrupt immune reconstitution may precipitate a severe 
immune reconstitution inflammatory syndrome (IRIS) which 
is manifested by worsening symptoms and MRI abnormali-
ties [83]. An IRIS-like rebound phenomenon can occur   
without intervention, as exemplified by the case described 
(Fig.  2). Other diseases associated with CNS immune   
suppression like toxoplasmosis [84], primary central nervous 
system lymphoma [85] and melanoma [86] have been   
reported but a clear association has not been established. 
  Hepatic injury has been reported in several patients and 
in one case series [87], half of the cases had features of auto-
immune hepatitis. So far, there have been no atypical infec-
tions that have been documented to affect the liver during 
natalizumab therapy. 
  The more common side effects of natalizumab are fatigue 
and allergic reactions. Headaches, chest discomfort, rigors 
and syncope have also been frequently reported. The symp-
toms are typically noted during the infusion or immediately 
after. Mild to moderate infections have been observed but 
there were no significant differences between the natalizu-
mab and the placebo treatment groups in the original pivotal 















Fig. (2). A 25 year old man with a diagnosis of MS had sudden 
change in neurologic status after discontinuation of natalizumab. He 
had been on therapy for two years with good response but 
natalizumab was discontinued due to concerns of increased risk for 
PML. He switched to glatiramer acetate but after three months from 
discontinuation of natalizumab, he had acute symptoms of ataxia 
and fatigue. MRI revealed multiple new T2/FLAIR hyperintensities 
and T1 enhancing lesions. He was treated with a 5 day course of 
methylprednisolone and his symptoms promptly resolved (case 
report and MRI courtesy of Ann Cabot, D.O.). 
RITUXIMAB 
  Rituximab is a monoclonal antibody that binds to the 
CD20 antigen in
 mature B lymphocytes. It causes depletion 
of its target cells through a combination of cell-mediated and 
complement-dependent
 cytotoxic effects and the promotion 
of apoptosis [88, 89]. Several preliminary studies have 
shown that rituximab can reduce inflammatory
 brain lesions 
and clinical relapses in MS [90, 91]. There are several case 
reports of its efficacy in refractory MG [92-97], CIDP [98-
101] and CNS involvement of systemic vasculitis [102, 103]. 
Ocrelizumab is a humanized monoclonal antibody similar to 
rituximab that is currently in phase II trials for the treatment 
of relapsing MS. 
  These antibodies have also been associated with PML. 
Although the original cases were in patients with non-
Hodgkin's lymphoma who were receiving chemotherapy, 
two cases of PML occured in patients with systemic lupus 
erythematosus [104]. A third case was reported to the FDA 
in 2009 in a patient with rheumatoid arthritis [105]. It is es-
timated that the rate of occurrence is about 2.2 per 100,000, 
significantly lower than what is seen in natalizumab. 
  Serious, sometimes fatal infections have been reported. 
Hepatitis B reactivation resulting in hepatic failure, fulmi-474    Current Neuropharmacology, 2011, Vol. 9, No. 3  Lallana and Fadul 
nant hepatitis and death have been seen in rituximab treated 
patients with hematologic malignancies [106]. In a phase II 
trial for MS, there were also mild to moderate infections of 
the upper respiratory tract, urinary tract and sinuses [90]. 
Frequently reported mild side effects include chills, head-
ache, nausea, pruritus, fever, fatigue, and throat irritation. 
ALEMTUZUMAB 
  Alemtuzumab is a humanized monoclonal antibody   
that targets the CD52 receptor, causing mononuclear cell 
depletion that can last for years [107]. In a prospective phase 
II MS study, it significantly reduced the rate of sustained
 
accumulation of disability and annualized rate of relapse 
when compared against interferon beta 1a [108]. 
  Paradoxically, autoimmunity is one of the most serious 
side effects of alemtuzumab, probably associated to regula-
tory lymphocyte depletion. Immune thrombocytopenic pur-
pura occured in 6 patients resulting in one death during the 
above referenced phase II trial [108]. Autoimmune thyroid 
disease was frequently found in the alemtuzumab treatment 
group and was associated with thyroid autoantibodies in   
96% of affected individuals. Graves' disease is associated 
with increased numbers of CD8
+ cells and a low production 
of memory CD4
+ cells 15-18 months after treatment [109]. 
These findings are consistent with previously established 
association of CD8
+ positive counts in Graves' disease   
[110]. 
  It frequently causes severe and persistent lymphopenia 
along with moderate to severe neutropenia, anemia and 
thrombocytopenia. Anaphylactoid infusion reactions which 
include pyrexia, chills, hypotension, urticaria, and dyspnea, 
were common but are a rare cause of discontinuation of 
treatment. Abnormal liver function tests are occasionally 
seen and are usually reversible. 
  Mild to moderate infections of the upper respiratory tract 
were common in the MS trial. There have been no reported 
cases of PML to date. 
FINGOLIMOD 
  The immune modulating drug FTY720 (fingolimod) in-
duces lymphopenia by revesibly redistributing lymphocytes 
from the circulation to the secondary lymphoid tissues. It is 
thought to act through sphingosine 1-phosphate (S1P) signal-
ing pathways to modulate chemotactic responses and regu-
late the recirculation of lymphocytes [111, 112]. In two 
phase III studies, it was shown to decrease the relapse rate, 
disability progression and number of new or enlarged lesions 
on T2 -weighted images, gadolinium-enhancing
  lesions,  
and brain-volume loss in patients with relapsing MS [113, 
114].  
  The S1P receptor also regulates heart rate [115], coronary 
artery blood flow [116] and blood pressure [117]. Atrial 
myocytes have the S1P3 receptors that fingolimod effec-
tively signals [112]. This interaction results in slowing of the 
sinoatrial node and reactivation of G-protein-activated potas-
sium channels 1 and 4. It is also theorized that fingolimod 
has similar effects on the atrioventricular (AV) node. Pre-
dictably, the most common adverse event in the clinical trials 
were bradycardia and AV block. The transient, dose depend-
ent decrease in heart rate occurred within one hour of the 
first dose of the medication. The majority of the patients who 
had bradycardia were reported to be asymptomatic while a 
few had symptoms that resolved within 24 hours without 
intervention [114, 118]. 
  The most frequently reported infections involved the up-
per respiratory and urinary tracts. Severe infections were 
seen, including herpes virus reactivations. There is also one 
case report of hemorrhagic focal encephalitis complicated by 
complex partial seizures after 7 months of treatment [119]. 
  The most common side effects are mild and include 
headache, fatigue, dizziness, musculoskeletal pain, cough 
and dyspnea. There are few reports of elevation of liver func-
tion tests, hypertension and leucopenia. 
CONCLUSION 
  The treatment of presumed autoimmune neurologic   
diseases has rapidly expanded in the last two decades. The 
research to date has resulted in the acceptance of immune 
suppressive drugs as an important regimen for neurologic 
diseases. Prior to the advent of these medications, corticos-
teroids were used widely, in some cases with little proven 
benefit, resulting in a high rate of long term side effects. 
Since then, the use of IVIg, mycophenolate, azathioprine, 
cyclosporine and tacrolimus has provided a better therapeutic 
ratio than corticosteroids in neuromuscular disease and neu-
rosarcoidosis. Cytotoxic chemotherapy has offered patients 
with MS, CNS vasculitis and neurosarcoidosis a therapeutic 
option when they become refractory to first line agents. An-
tibodies and other targeted biologic agents have the potential 
for improved disease control in MS, as well as in other auto-
immune neurologic illnesses. However, it must be pointed 
out that only mitoxantrone, natalizumab and IVIg have FDA 
approved indications in neurologic diseases. Great care and 
diligence must be made whenever deciding to use these 
medications as recent clinical trials have taught us about 
unexpected adverse events. As we have outlined here, there 
can be significant problems associated with these treatments, 
the most important of which are hematotoxicity, increased 
infection rate, and carcinogenicity. With this knowledge we 
proceed with vigilance but we anticipate that the advances  
in our understanding of the immune system will bring   
more targeted therapies that will not only result in improved 
efficacy but also decreased toxicity.  
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